Inflammatory bowel disease drug trial starts vs Autoimmune cell therapy and T-cell engager trial starts

In 2025, inflammatory bowel disease drug trial starts worldwide stood at 94, against 112 for autoimmune cell therapy and T-cell engager trial starts.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Inflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts

Unit: count · 12 observations

2 series · one axis
Inflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts: GlobalInflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts. 2 indicators on one axis: Inflammatory bowel disease drug trial starts, Autoimmune cell therapy and T-cell engager trial starts. 12 observations from 2020 to 2025, ranging from 2 to 112. Latest values: Inflammatory bowel disease drug trial starts 94 (2025); Autoimmune cell therapy and T-cell engager trial starts 112 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 94 112 Inflammatory bowel disease drug trial starts Autoimmune cell therapy and T-cell engager trial starts
Inflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts: GlobalInflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts. 2 indicators on one axis: Inflammatory bowel disease drug trial starts, Autoimmune cell therapy and T-cell engager trial starts. 12 observations from 2020 to 2025, ranging from 2 to 112. Latest values: Inflammatory bowel disease drug trial starts 94 (2025); Autoimmune cell therapy and T-cell engager trial starts 112 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 94 112 Inflammatory bowel disease drug trial starts Autoimmune cell therapy and T-cell engager trial starts
Inflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts: GlobalInflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts. 2 indicators on one axis: Inflammatory bowel disease drug trial starts, Autoimmune cell therapy and T-cell engager trial starts. 12 observations from 2020 to 2025, ranging from 2 to 112. Latest values: Inflammatory bowel disease drug trial starts 94 (2025); Autoimmune cell therapy and T-cell engager trial starts 112 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 94 112 Inflammatory bowel disease drug trial starts Autoimmune cell therapy and T-cell engager trial starts
View the underlying data
Inflammatory bowel disease drug trial starts and Autoimmune cell therapy and T-cell engager trial starts: Global
Indicator Period Type Value
Inflammatory bowel disease drug trial starts 2025 Actual 94
Inflammatory bowel disease drug trial starts 2024 Actual 87
Inflammatory bowel disease drug trial starts 2023 Actual 95
Inflammatory bowel disease drug trial starts 2022 Actual 88
Inflammatory bowel disease drug trial starts 2021 Actual 88
Inflammatory bowel disease drug trial starts 2020 Actual 73
Autoimmune cell therapy and T-cell engager trial starts 2025 Actual 112
Autoimmune cell therapy and T-cell engager trial starts 2024 Actual 91
Autoimmune cell therapy and T-cell engager trial starts 2023 Actual 17
Autoimmune cell therapy and T-cell engager trial starts 2022 Actual 6
Autoimmune cell therapy and T-cell engager trial starts 2021 Actual 7
Autoimmune cell therapy and T-cell engager trial starts 2020 Actual 2

Shared periods

Side by side

6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Inflammatory bowel disease drug trial starts Autoimmune cell therapy and T-cell engager trial starts
2020 73 ClinicalTrials.gov 2 ClinicalTrials.gov
2021 88 ClinicalTrials.gov 7 ClinicalTrials.gov
2022 88 ClinicalTrials.gov 6 ClinicalTrials.gov
2023 95 ClinicalTrials.gov 17 ClinicalTrials.gov
2024 87 ClinicalTrials.gov 91 ClinicalTrials.gov
2025 94 ClinicalTrials.gov 112 ClinicalTrials.gov

Provenance

Where these numbers come from

Inflammatory bowel disease drug trial starts

Count of interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Autoimmune cell therapy and T-cell engager trial starts

Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related